Details for New Drug Application (NDA): 021712
✉ Email this page to a colleague
The generic ingredient in FLUXID is famotidine. There are eighteen drug master file entries for this compound. One hundred and forty suppliers are listed for this compound. Additional details are available on the famotidine profile page.
Summary for 021712
| Tradename: | FLUXID |
| Applicant: | Ucb Inc |
| Ingredient: | famotidine |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 021712
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, ORALLY DISINTEGRATING;ORAL | Strength | 20MG | ||||
| Approval Date: | Sep 24, 2004 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, ORALLY DISINTEGRATING;ORAL | Strength | 40MG | ||||
| Approval Date: | Sep 24, 2004 | TE: | RLD: | No | |||||
Expired US Patents for NDA 021712
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Ucb Inc | FLUXID | famotidine | TABLET, ORALLY DISINTEGRATING;ORAL | 021712-001 | Sep 24, 2004 | 6,024,981 | ⤷ Get Started Free |
| Ucb Inc | FLUXID | famotidine | TABLET, ORALLY DISINTEGRATING;ORAL | 021712-002 | Sep 24, 2004 | 6,221,392 | ⤷ Get Started Free |
| Ucb Inc | FLUXID | famotidine | TABLET, ORALLY DISINTEGRATING;ORAL | 021712-002 | Sep 24, 2004 | 6,024,981 | ⤷ Get Started Free |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription
